stockrow
Friday 6 November 2026
Export KZIA’s income statement to Excel — free account
Novogen Limited
KZIA Healthcare Biotechnology
Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
7.22
0.22
+3.14%
Follow KZIA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Dec ’25 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 0 | 0 | 1 | 1 | 11 | 0 | 0 | 2 | 1 | — | +9.2% | 1 | 0 | 0 | (36.6%) | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | (6,577.76) | 100.00 | 100.00 | 100.00 | 0.00 | 0.0 pt | ||||||
| EBT | (17) | (8) | (5) | (8) | (9) | (7) | (18) | (14) | (18) | (15) | (32) | (1.5%) | ||||||
| EBT margin, % | (2,993.79) | (4,365.53) | (5,328.82) | (675.30) | (1,203.27) | (58.49) | (92,597.45) | (89,485.26) | (1,085.00) | (1,180.84) | 0.00 | +1,813.0 pt | ||||||
| Net income | (17) | (8) | (5) | (7) | (8) | (6) | (18) | (14) | (18) | (13) | (46) | (2.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 6.51 | 2.01 | 0.95 | 9.73 | 4.88 | 48.35 | 0.07 | 0.04 | 3.10 | 1.12 | 0.00 | (17.7%) | |||||
| Earnings | (195.07) | (85.94) | (48.50) | (62.50) | (57.30) | (26.50) | (67.50) | (38.00) | (33.30) | (12.24) | (0.22) | (26.5%) | ||||||
| Cash flow | (192.23) | (92.10) | (69.37) | (41.76) | (40.49) | (28.93) | (62.34) | (27.68) | (11.91) | (7.85) | 0.00 | (29.9%) | ||||||
| Capex | (8.38) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (200.60) | (92.26) | (69.37) | (41.76) | (40.49) | (28.93) | (62.34) | (27.68) | (11.91) | (7.85) | 0.00 | (30.2%) | ||||||
| Book value | 544.44 | 204.08 | 154.11 | 88.28 | 64.92 | 120.20 | 51.05 | 22.01 | (12.46) | (4.91) | 0.00 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | — | +32.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | 1.58 | 0.29 | 0.17 | 0.19 | 0.38 | 0.87 | 0.13 | 0.06 | 0.03 | 0.10 | 1.71 | 0.4 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (9) | (7) | (5) | (6) | (7) | (17) | (10) | (6) | (9) | (27) | (6.9%) | |||||
| Capex | (1) | 0 | — | — | — | — | — | — | — | — | 0 | (97.9%) | ||||||
| Free cash flow | (17) | (9) | (7) | (5) | (6) | (7) | (17) | (10) | (6) | (9) | (27) | (7.4%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 45 | 11 | 4 | 4 | 4 | 16 | 2 | 2 | (13) | (6) | 30 | n/m | |||||
| Net debt | (46) | (11) | (5) | (4) | (6) | (21) | (4) | (2) | (1) | (3) | (46) | (27.4%) | ||||||
| Shareholders’ equity | 47 | 19 | 15 | 10 | 9 | 28 | 14 | 8 | (7) | (5) | 31 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (39.27) | (21.22) | (19.14) | (39.72) | (54.66) | (21.37) | (52.01) | (62.24) | (106.23) | (148.30) | 0.00 | (109.0) pt | |||||
| ROIC | (1,515.06) | (58.03) | (11.29) | (62.05) | (141.33) | (38.58) | (119.30) | (175.20) | 0.00 | 0.00 | 0.00 | +1,515.1 pt | ||||||
| ROE | (41.00) | (24.51) | (27.52) | (58.60) | (85.26) | (33.32) | (85.55) | (127.36) | (2,275.77) | 224.48 | 0.00 | +265.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 16 | 16 | 5 | 5 | 8 | 11 | 13 | — | 12 | 6 | — | (10.3%) | |||||
| Revenue/emp, $m | 0.03 | 0.01 | 0.02 | 0.22 | 0.09 | 1.03 | 0.00 | 0.00 | 0.14 | 0.21 | — | +21.8% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2025 · fundamentals updated 26 Oct 2026
Novogen Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RLYB Rallybio Corporation | $84.5M | 3.3× | — (loss-making) | 0.00% | n/m | +65.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EQ Equillium, Inc. | $84.3M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GNLX Genelux Corporation | $82.4M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KZIA Novogen Limited | $80.0M | — (loss-making) | — (loss-making) | — | −32.67% (below 0%: shrinking) | −51.71% (below 0%: shrinking) | 0.00% | 0.00% | |
| ATRA Atara Biotherapeutics, Inc. | $79.9M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $79.6M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $78.9M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| NRXS Neuraxis, Inc. | $76.7M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| CLLS Cellectis S.A. | $74.5M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| Median of peers | $79.8M | — | — | −26.16% | — | +3.42% | 97.41% | (110.16%) |